MIRAPEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MIRAPEX (MIRAPEX).
Dopamine receptor agonist (D3 > D2 > D4) with activity at α2-adrenergic and 5-HT1A receptors; increases dopamine receptor activation in striatum.
| Metabolism | Minimal hepatic metabolism; ~90% excreted unchanged in urine via active tubular secretion; CYP450 involvement is negligible. |
| Excretion | Renal elimination accounts for approximately 90% of total clearance, with about 80% recovered as unchanged parent drug in urine. Biliary/fecal excretion is minimal (<10%). |
| Half-life | The terminal elimination half-life is 8–12 hours in healthy adults, allowing for three-times-daily dosing. In elderly patients, half-life may be prolonged to 12–14 hours due to age-related decline in renal function. |
| Protein binding | Approximately 15% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 7 L/kg, indicating extensive distribution into tissues, including the central nervous system. |
| Bioavailability | Absolute oral bioavailability is >90%, with peak plasma concentrations achieved within 1–2 hours. Food does not significantly alter absorption. |
| Onset of Action | Oral: 1–2 hours; peak effect on motor symptoms occurs within 2–4 hours. |
| Duration of Action | Symptom relief lasts 8–12 hours, consistent with the dosing interval of three times daily. Effects on motor fluctuations may persist longer with extended-release formulations. |
Initial: 0.375 mg orally once daily; titrate gradually based on efficacy and tolerability. Usual effective dose: 1.5-4.5 mg daily in 3 divided doses. Maximum dose: 4.5 mg/day.
| Dosage form | TABLET |
| Renal impairment | For CrCl > 60 mL/min: no adjustment. CrCl 35-59 mL/min: initial 0.375 mg once daily; maximum 2.25 mg/day. CrCl 15-34 mL/min: initial 0.375 mg every other day; maximum 1.5 mg/day. CrCl < 15 mL/min: not recommended. |
| Liver impairment | No specific dosage adjustment guidelines for hepatic impairment. Use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established for pediatric patients. |
| Geriatric use | Start at low end of dosing range (0.375 mg once daily) due to increased risk of hallucinations, somnolence, and orthostatic hypotension; titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MIRAPEX (MIRAPEX).
| Breastfeeding | Pramipexole is excreted in rat milk, but it is not known whether it is excreted in human milk. The M/P ratio is unknown. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, pramipexole caused postimplantation loss, decreased fetal weight, and increased incidence of skeletal variations at maternally toxic doses. Risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus. First trimester: limited data; second and third trimesters: no specific trimester risks delineated. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to pramipexole or any component of the formulation"]
| Precautions | ["Sudden onset of sleep and somnolence","Postural hypotension","Hallucinations and psychotic-like behavior","Impulse control disorders / compulsive behaviors","Dyskinesia exacerbation in Parkinson's","Fibrotic complications (retroperitoneal fibrosis, pulmonary fibrosis) reported with ergot derivatives; not directly but observe","Rebound symptoms on discontinuation","Caution in renal impairment (dose adjustment required)","Risk of melanoma (monitor skin lesions)"] |
Loading safety data…
| Fetal Monitoring | Monitor for excessive sedation, orthostatic hypotension, and dyskinesias in the mother. Fetal monitoring: consider periodic ultrasound to assess fetal growth and development given animal findings; no specific fetal monitoring guidelines exist. |
| Fertility Effects | In animal studies, pramipexole caused prolonged estrous cycles and reduced fertility in female rats at high doses. In male rats, no impairment of fertility was observed. Effects on human fertility are unknown. |